Substituted nicotinimide inhibitors of BTK for treating cancer
US12162873B2 · kind B2 · utility
0Cited by
0References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 27, 2023 |
| Grant date | Dec 10, 2024 |
| Priority date | — |
| Expiry date | Oct 27, 2043 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D413/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compounds of Formula I, as shown below and defined herein: and pharmaceutically acceptable salts, syntheses, intermediates, formulations, and methods of treating diseases including cancer, inflammation, and autoimmune disease mediated at least in part by Bruton's Tyrosine Kinase (BTK).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.